News
Tarja Stenvall

Bavarian Nordic has found its new CEO

Six months after Paul Chaplin said he was stepping down as CEO of Bavarian Nordic, the Danish biopharma has named Tarja Stenvall to the role.

News
MSD hits a hurdle with its LAG-3 programme

MSD hits a hurdle with its LAG-3 programme

MSD's combination of PD-1 inhibitor Keytruda and experimental LAG-3 inhibitor favezelimab has failed a phase 3 trial in patients with previously treated PD-L1-positive microsatellite stable

Debates & Insights

News

News
Tarja Stenvall

Bavarian Nordic has found its new CEO

Six months after Paul Chaplin said he was stepping down as CEO of Bavarian Nordic, the Danish biopharma has named Tarja Stenvall to the role.

Press Releases

Newsletters and Deep Dive
digital magazine

Views & Analysis

Webinars

Podcasts

Video

White Papers

Event

Partner Content

Debates & Insight